Open an account

AIM ImmunoTech

AIM · NYSE American

$0.1662+$0.0031 (+1.90%)TodayMarket closed ·
Prev close $0.1631

About AIM

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 19 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Employees
19
Headquarters
Ocala, Florida
Listed
Jul 12, 1996
Sector
Health Care
Industry
Biotechnology
Website
aimimmuno.com

AIM key statistics

Market cap
6.63M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.07M
Volume
208.80K
Open price
$0.1633
High today
$0.1699
Low today
$0.1633
52 Week high
$2.79
52 Week low
$0.1599

AIM ImmunoTech (AIM) at a glance

AIM ImmunoTech (AIM) last traded at $0.1662, with a market cap of 6.63M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1633 and $0.1699. The current price is 1.8% above the day's low and 2.2% below its high.

Volume so far is 208.80K shares, below the average of 1.07M shares a day.

Over the past year AIM ImmunoTech has ranged from $0.1599 to $2.79, and now sits 0% of the way up that range.

AIM ImmunoTech met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.43 per share against an estimate of -$0.1717.

The average analyst price target is $4.34, 2508.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $4.34
Low
$1.51
Now
$0.1662
High
$7.35

AIM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 35.8% on average.

  1. Q3 FY24: reported -$6.39 per share against an estimate of -$10.09
  2. Q4 FY24: reported -$9.99 per share against an estimate of -$11.60
  3. Q1 FY25: reported -$4.99 per share against an estimate of -$8.07
  4. Q2 FY25: reported -$3.68 per share against an estimate of -$8.07
  5. Q3 FY25: reported -$1.57 per share against an estimate of -$0.9838
  6. Q4 FY25: reported -$1.44 per share against an estimate of -$0.9737
  7. Q1 FY26: reported -$0.57 per share against an estimate of -$0.3737
  8. Q2 FY26: reported -$0.43 per share against an estimate of -$0.1717

AIM news

  • Press releaseGlobe Newswire

    AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    Nasdaq Jumps 200 Points; US Adds 115,000 Jobs In April

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

Similar companies

Companies in the same industry as AIM ImmunoTech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.